PMID- 32499542
OWN - NLM
STAT- MEDLINE
DCOM- 20210119
LR  - 20210604
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jun 4
TI  - Thiol Groups as a Biomarker for the Diagnosis and Prognosis of Prostate Cancer.
PG  - 9093
LID - 10.1038/s41598-020-65918-w [doi]
LID - 9093
AB  - Oxidative stress (OS) is associated with the onset of prostate cancer (PCa). The 
      aims of this study are to examine whether OS biomarkers may be employed as 
      external validating criteria for the diagnosis PCa. This case-control study 
      recruited 204 subjects, 73 patients with PCa, 67 patients with benign prostate 
      hyperplasia (BPH), and 64 healthy controls (HC) and assayed plasma 
      prostate-specific antigen (PSA), protein thiol (-SH) groups, lipid 
      hydroperoxides, carbonyl proteins (PCB), advanced oxidation protein products 
      (AOPP), and total radical-trapping antioxidant parameter (TRAP). -SH groups were 
      significantly and inversely associated with PSA levels. PCa was characterized by 
      lowered -SH groups and red blood cell TRAP levels, and higher PSA, AOPP and PCB 
      levels as compared with BPH and HC. Support vector machine with 10-fold 
      cross-validation showed that PSA values together with -SH groups, PCB and AOPP 
      yielded a cross-validation accuracy of 96.34% for the differentiation of PCa from 
      BPH and HC. The area under the ROC curve using PSA and -SH differentiating PCa 
      from BPH and controls was 0.945. Moreover, lowered -SH, but not PSA, are 
      associated with PCa metastasis and progression. Inflammatory biomarkers were not 
      associated with PCa or BPH. PCa, its progression and metastatic PCa are 
      characterized by lowered antioxidant defenses, especially lowered thiol groups, 
      and increased oxidative stress toxicity, suggesting that these processes play a 
      key role in the pathophysiology of PCa. An algorithm based on -SH and PSA values 
      may be used to differentiate patients with PCa from those with BPH and controls.
FAU - Koike, Alexsandro
AU  - Koike A
AD  - Cancer Institute of Londrina, Laboratory of Research in Applied Immunology, 
      University of Londrina, Londrina, Parana, Brazil.
FAU - Robles, Brunna Emanuella Franca
AU  - Robles BEF
AD  - Laboratory of Research in Applied Immunology, University of Londrina, Londrina, 
      Parana, Brazil.
FAU - da Silva Bonacini, Ana Gabriela
AU  - da Silva Bonacini AG
AD  - Laboratory of Research in Applied Immunology, University of Londrina, Londrina, 
      Parana, Brazil.
FAU - de Alcantara, Camila Cataldi
AU  - de Alcantara CC
AUID- ORCID: 0000-0002-9181-3925
AD  - Laboratory of Research in Applied Immunology, University of Londrina, Londrina, 
      Parana, Brazil.
FAU - Reiche, Edna Maria Vissoci
AU  - Reiche EMV
AD  - Department of Pathology, Clinical Analysis and Toxicology, Laboratory of Research 
      in Applied Immunology, University of Londrina, Londrina, Parana, Brazil.
FAU - Dichi, Isaias
AU  - Dichi I
AD  - Department of Internal Medicine, University of Londrina, Londrina, Parana, 
      Brazil.
FAU - Maes, Michael
AU  - Maes M
AD  - IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, 
      Victoria, Australia.
FAU - Cecchini, Rubens
AU  - Cecchini R
AD  - Department of Pathology Sciences, University of Londrina, Londrina, Parana, 
      Brazil.
FAU - Simao, Andrea Name Colado
AU  - Simao ANC
AD  - Department of Pathology, Clinical Analysis and Toxicology, Laboratory of Research 
      in Applied Immunology, University of Londrina, Londrina, Parana, Brazil. 
      deianame@yahoo.com.br.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200604
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Sulfhydryl Compounds)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Case-Control Studies
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress
MH  - Prognosis
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Hyperplasia/diagnosis
MH  - Prostatic Neoplasms/*diagnosis/etiology
MH  - Sulfhydryl Compounds/*blood
PMC - PMC7272452
COIS- The authors declare no competing interests.
EDAT- 2020/06/06 06:00
MHDA- 2021/01/20 06:00
PMCR- 2020/06/04
CRDT- 2020/06/06 06:00
PHST- 2019/07/05 00:00 [received]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/06/06 06:00 [entrez]
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/01/20 06:00 [medline]
PHST- 2020/06/04 00:00 [pmc-release]
AID - 10.1038/s41598-020-65918-w [pii]
AID - 65918 [pii]
AID - 10.1038/s41598-020-65918-w [doi]
PST - epublish
SO  - Sci Rep. 2020 Jun 4;10(1):9093. doi: 10.1038/s41598-020-65918-w.